期刊文献+

高磷血症维持性血液透析患者的临床分析 被引量:6

The Clinical Analysis of Hyperphosphatemia in Maintenance Hemodialysis Patients
原文传递
导出
摘要 目的:比较不同血磷水平的维持性血液透析的尿毒症患者的临床表现和实验室指标,探讨其临床意义。方法:选择上海交通大学医学院附属新华医院(崇明)肾内科28例高血磷(SP>1.6mmol/L)的维持性血液透析患者为病例组,30例血磷正常(SP≤1.6mmol/L)维持性血液透析患者为对照组,比较两组患者的原发病组成,年龄,性别,透析龄,皮肤瘙痒发生率,腰背痛发生率,血钙,血碳酸氢根,血红蛋白,红细胞压积,血碱性磷酸酶,肾功能,血浆白蛋白水平及左心室肥厚发生率。结果:病例组与对照组在原发病组成,年龄(43.2±9.8岁vs 40.5±12.2岁),男女性别比例(16/12 vs.17/13),透析龄(32.56±6.71月vs.35.43±5.82月)等方面无显著性差异(P>0.05),有可比性,在血红蛋白(83.22±6.71g/L vs 103.36±5.84g/L),红细胞压积(24.83±1.92%vs.30.76±1.52%),血钙(1.71±0.16mmol/L vs.2.23±0.21 mmol/L),血碳酸氢根(14.2±3.1mmol/L vs 20.6±4.9 mmol/L),血碱性磷酸酶(124.26±16.33U/L vs.61.47±14.91 U/L),皮肤瘙痒发生率(22/28 vs.7/30),腰背痛发生率(19/28 vs.6/30),左心室肥厚发生率(20/28 vs 12/30),有显著性差异(P<0.05),肌酐(956±142mmol/L vs.923±156 mmol/L),尿素氮(23.1±6.3mmol/L vs.24.8±8.9mmol/L),血浆白蛋白(30.5±3.8g/L vs.31.2±2.9g/L),无显著性差异(P>0.05)。结论:伴有高磷血症的维持性血液透析患者与血磷正常的患者相比,血碱性磷酸酶,皮肤瘙痒发生率,腰背痛发生率及左心室肥厚发生率较高,而血钙,血碳酸氢根,血红蛋白及红细胞压积较低,有一定差异。 Objective: To compare the clinical feature and laboratory examination indexes of different serum phosphorus levels in uremia patients treated with maintenance hemodialysis and explore its clinical significance. Methods:According to the serum phosphorus levels, 58 maintenance hemodialysis patients from department ofnephrology, Xinghua Hospital Affiliated to Shanghai Jiaotong Universi- ty School of Medicine were divided into two groups, including 28 cases of case group (SP〉1.6mmol/L) and 30 cases of control group (SP〈 1.6mmol/L). The protopathy, age, gender, duration of hemodialysis, blood calcium, bicarbonate, hemoglobin, hematocrit, blood alkaline phosphatase, renal function, level of plasma albumin and incidence of itchy skin, low back pain and left ventricular hypertrophy between the two groups were all compared and analyzed. Results: Two groups of patients in basic information including protopathy, age (43.2± 9.8 years vs. 40.5± 12.2 years), sex ratio(16/12 vs.17/13), duration of hemodialysis (32.56± 6.71 month vs.35.43± 5.82 month) were no significant difference (P〉0.05). There were significant difference between case group and control group on the hemoglobin (83.22± 6.71g/L vs. 103.36± 5.84g/L), hematocrit (24.83±1.92% vs. 30.76± 1.52%), blood calcium (1.71± 0.16mmol/L vs. 2.23± 0.21 mmol/L), bicarbonate (14.2± 3.1mmol/L vs. 20.6±4.9 retool/L), blood alkaline phosphatase (124.26± 16.33U/L vs. 61.47± 14.91 U/L), incidence of itchy skin (22/28 vs. 7/30), low back pain (19/28 vs. 6/30), and left ventricular hypertrophy (20/28 vs. 12/30)(P〈0.05), but the creatinine (956±142mmol/L vs. 923± 156 mmol/L), urea nitrogen (23.1 ± 6.3mmol/L vs. 24.8± 8.9 mmol/L), plasma albumin (30.5± 3.8g/L vs. 31.2± 2.9g/L) were not statistically significant (P〉0.05). Conclusions: Compared with patients with normal serum phosphorus, maintenance hemodialysis patients with hyperphosphatemia has higher blood alkaline phosphatase, incidence of itchy skin, low back pain and left ventricular hypertrophy, and lower blood calcium, bicarbonate, hemoglobin, hematocrit. Words:
出处 《现代生物医学进展》 CAS 2011年第22期4276-4278,共3页 Progress in Modern Biomedicine
关键词 高磷血症 继发性甲状旁腺功能亢进 血液透析 Hyperphosphatemia Secondary hyperparathyroidism Hemodialysis
  • 相关文献

参考文献11

二级参考文献17

  • 1董一民,周龙珍,孙丽萍.中药外洗配合血液透析治疗尿毒症瘙痒的效果观察[J].中国实用医药,2007,2(12):62-63. 被引量:18
  • 2唐万欣,付平,杨宁,周莉,黄颂敏,许国章.高通量透析与低通量透析对尿毒症皮肤瘙痒疗效的比较研究[J].临床荟萃,2005,20(17):964-967. 被引量:8
  • 3黄颂敏.血液透析与钙性尿毒症性小动脉病[J].中国实用内科杂志,2005,25(10):876-878. 被引量:16
  • 4MOVILLI E,CANCARINI G C,ZANI R,et al.Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haenodialysis patients[J].Nephrol Dial Transplant,2001,16 (1):111-114.
  • 5LETO E,BILAL F,OSMIC I.Efficiency of high-flow dialyzers in removal of beta-2-microglobulin[J].Med Arh,2001,55 (4):225 -226.
  • 6CLARK W R,HAMBURGER R J,LYSAGHT M J.Effect of membrane composition and structure on solute removal and biocompatibility in hemodialysis[J].Kidney Int,1999,56 (6):2005-2015.
  • 7LOCATELLI F,DEL V L,ANDRULLI S.Dialysis:its role in optimizing recombinant erythropoietin treatment[J].Nephrol Dial Transplant,2001,16 (Suppl 7):29-35.
  • 8COVIC A,GOLDSMITH D J,HILL K,et al.Urea kinetic modelling--are any of the ' bedside' Kt/V formulae reliable enough[J] ? Nephrol Dial Transplant,1998,13 (12):3138-3146.
  • 9Szepietowski JC,Sikora M,Kusztal M,et al.Uremic pruritus:a clinical study of maintenance hemodialysis patients[J].J Dermatol,2002,29(10):621-627.
  • 10Guefin AP,london GM,Marchais S J,et al.Arterial stiffening and vascular caleieations in end-stage rend disease[J].Nephrol Dial Tramsplant,2000,15:1014-1021.

共引文献15

同被引文献52

  • 1郑宏,高洁.不同血液净化方法治疗尿毒症患者皮肤瘙痒[J].临床军医杂志,2010,38(6):1037-1039. 被引量:16
  • 2陈香美,王海燕.提高慢性肾脏病的知晓率、治疗率和控制率减轻对国民健康的危害[J].中华内科杂志,2006,45(6):441-442. 被引量:65
  • 3Checheri~ IA,Smarandache D,David C,et al. Vascular calcifications in chronic kidney disease--clinical management. Rom J Morphal Embryo1,2012,53( 1 ) :7-13.
  • 4Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med,2010,362(14) : 1312-1324.
  • 5Raggi P,Kleerekoper M. Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease. Clin J Am Soc Nephrol, 2008,3 (3) : 836-843.
  • 6Navaneethan SD, Palmer SC, Craig JC,et al. Benefits and harms of phosphate binders in CKD:a systematic review of randomized controlled trials. Am J Kidney Dis, 2009,54 ( 4 ) : 619-637.
  • 7Sampathkumar K. Niacin and analogs for phosphate control in dialysis--perspective from a developing country. Int Urol Nephrel, 2009,41(4) :913-918.
  • 8Foley RN, Collins A J, Herzog CA, et al. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Sac Nephrol, 2009,20 ( 2 ) : 397 -404.
  • 9Hutchison A J, Barnett ME, Krause R J, et al. Lanthanum carbonate treatment, for up to 6 years,is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis. Clin Nephrol, 2009,71 (3) : 286-295.
  • 10Delanaye P,Weekers L,Krzesinski JM. Diarrhea induced by high doses of nicotinamide in dialysis patients. Kidney Int,2006,69 (10) : 1914.

引证文献6

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部